Objectives: To determine the histologic types of testicular tumors and identify associated risk factors.
Methods: Data on clinical presentation, age, race, history of cryptorchidism or testicular trauma and histologic types, on each patient with testis tumor, were abstracted from medical records and the pathology register.
Results: Of 14 tumors, 11 were malignant. Five were Burkitt's and 2 non-Burkitt's lymphomas, 1 plasmocytoma and 3 seminomas. None of the seminomas occurred in black Africans.
Conclusion: The epidemiology and histology of testis tumors in Yaounde differs considerably from other reported series. Burkitt's lymphoma is the commonest tumor. This alters the approach to the management of testicular masses. Race and geography seem to be important in the occurrence of testes tumors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000474194 | DOI Listing |
Melanoma antigen gene-A2 (MAGE-A2) is one of the most cancer-testis antigens overexpressed in a variety of malignancies. However, the expression of MAGE-A2 for clinical values in the pathophysiology of renal cell carcinoma (RCC) is unknown. For the first time, the present study was conducted to examine the expression and prognostic significance of MAGE-A2 expression in clear cell RCC (ccRCC).
View Article and Find Full Text PDFInt J Mol Sci
January 2025
Oncology Institute of Southern Switzerland (IOSI), Ente Ospedaliero Cantonale (EOC), 6500 Bellinzona, Switzerland.
Aggressive variant prostate cancer (AVPC) is characterized by a molecular signature involving combined defects in , , and/or (AVPC-TSGs), identifiable through immunohistochemistry or genomic analysis. The reported prevalence of AVPC-TSG alterations varies widely, reflecting differences in assay sensitivity, treatment pressure, and disease stage evolution. Although robust clinical evidence is still emerging, the study of AVPC-TSG alterations in prostate cancer (PCa) is promising.
View Article and Find Full Text PDFHCA Healthc J Med
December 2024
Menorah Medical Center, Overland Park, KS.
Background: Testicular seminoma is the most common malignant tumor of the testis. It occurs at a rate of 5 per 100 000 men, primarily between the ages of 15 to 34. While seminomas typically occur in the testis, other primary sites include the mediastinum, the retroperitoneum, or other extra-gonadal sites.
View Article and Find Full Text PDFFront Immunol
January 2025
Molecular Immunology and Gene Therapy, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
Generation of high avidity T cell receptors (TCRs) reactive to tumor-associated antigens (TAA) is impaired by tolerance mechanisms, which is an obstacle to effective T cell therapies for cancer treatment. NY-ESO-1, a human cancer-testis antigen, represents an attractive target for such therapies due to its broad expression in different cancer types and the restricted expression in normal tissues. Utilizing transgenic mice with a diverse human TCR repertoire, we isolated effective TCRs against NY-ESO-1 restricted to HLA-A*02:01.
View Article and Find Full Text PDFAppl Immunohistochem Mol Morphol
January 2025
Department of Molecular Pathology, Institute of Health Sciences, Dokuz Eylül University.
PRAME is a cancer testis antigen whose expression is limited in normal tissues but is increased in cancers. Although there are studies revealing its oncogenic and immunogenic role, the relationship between PRAME expression and immunity in melanomas is not very clear. We aimed to reveal the relationship between PRAME expression and clinicopathologic parameters, immunologic markers, survival in melanomas.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!